Research Synthesis: Exercise Effects

Research Synthesis: Exercise Effects

Abstract

Evidence-honesty note: 70/78 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Physical exercise is widely promoted as a primary intervention to mitigate the physiological decline of aging, yet the magnitude and consistency of its benefits across diverse clinical domains remain a subject of rigorous scrutiny.

This evidence synthesis utilized an AI-assisted structured audit approach to integrate findings from 78 curated reference papers, systematically mapping effect directions and mechanistic endpoints against clinical outcome classes.

Similarly, a 5-year aerobic exercise intervention in the Generation 100 study demonstrated significant preservation of sarcopenia parameters compared to control groups (P < 0.001), suggesting long-term maintenance of muscle integrity.

This discordance extends to functional domains, where network meta-analyses report significant gains in grip strength (MD = 2.38, 95%CI = 1.33-3.43) and gait speed, yet specific trials targeting cognitive frailty via Baduanjin exercise failed to demonstrate superiority over electroacupuncture.

Consequently, while exercise interventions consistently improve surrogate markers such as blood pressure and triglycerides (-8.56 mg/dL, 95% CI: -16.72, -0.40), the translation of these mechanistic benefits into guaranteed hard-outcome validity remains complex.

The synthesis concludes that the anti-aging case for exercise is promising but context-dependent; context-specific signals in cardiometabolic health coexist with mixed or sparse evidence in inflammation and frailty, indicating that boundary conditions for exercise prescription require further establishment.

Evidence-abstraction note. The 78 retained reference papers are not 78 independent primary clinical trials: 70 are review, indirect, or mechanistic source-level summaries, and 8 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Introduction

The geroscience hypothesis proposes that targeting fundamental aging biology — rather than individual diseases in isolation — may compress morbidity and extend functional years. Under this framework, Exercise Effects has been proposed as a candidate geroprotective intervention because a single behavioral stimulus appears to engage multiple hallmarks of aging simultaneously, from mitochondrial quality control to immune recalibration. Acute and subacute aerobic exercise, for example, increased soluble Klotho levels (SMD 0.69, 95% CI 0.41–0.97) in healthy individuals (Oliveira 2026), and higher circulating α-Klotho has been associated with lower odds of frailty (Guldan 2026). It remains uncertain, however, whether transient biomarker shifts translate into durable healthspan gains or whether Exercise Effects merely modulates downstream risk markers without altering the underlying rate of biological aging. The tension between mechanistic plausibility and clinical proof of concept frames the rationale for this synthesis.

Exercise Effects is often described as a polypill, yet its regulatory and clinical history differs fundamentally from that of pharmaceutical agents. Whether structured Exercise Effects can reverse or merely slow such decline in community-dwelling adults remains an open question. Long-term attrition rates in RCTs of older adults, estimated at roughly 20% (Schulz 2010), further complicate definitive conclusions about sustained benefit.

This synthesis addresses cross-outcome tensions in the Exercise Effects literature by separating clinical/functional evidence from mechanistic/biomarker evidence and applying structured evidence weighting across 78 curated reference papers. The Exercise Effects anti-aging case as currently constituted is incomplete: positive signals appear in frailty and contextual domains, null findings dominate cardiometabolic outcomes, and negative signals surface in select immune and cognitive contexts. By mapping cross-study disagreements across outcome classes, this work aims to clarify where mechanistic promise outpaces clinical proof and where the field should prioritize definitive trials.

Scope of the synthesis

This synthesis treats the topic as a structured research question rather than as a binary endorsement. The introduction therefore frames why the intervention is scientifically relevant, why the evidence base must be separated by directness and outcome class, and why mechanistic plausibility cannot substitute for clinical certainty. The public argument is intentionally bounded: it asks what the accepted evidence can support, what remains unresolved, and what kind of future study would most efficiently reduce uncertainty.

The research question is interpreted through design, population, and endpoint boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

Background

Preclinical and mechanistic investigations provide the biological plausibility scaffold for the Exercise Effects anti-aging narrative, though the specific pathway claims that can be grounded in this corpus are narrower than the rhetoric might suggest. Acute and subacute aerobic exercise has been shown to increase soluble Klotho levels in both healthy individuals and diseased populations (SMD 0.69; 95%CI 0.41–0.97 for acute exercise), a finding with potential implications for fibroblast growth factor signaling, phosphate homeostasis, and insulin sensitivity (Oliveira 2026). Higher circulating α-Klotho levels are in turn significantly associated with lower odds of frailty (Guldan 2026), establishing a plausible mechanistic bridge between exercise-induced Klotho modulation and frailty risk reduction, although the causal directionality remains unresolved. Exercise has also been reported to increase neuronal extracellular vesicle-derived insulin signaling biomarkers after a single bout (Malin 2026), suggesting a direct link between acute physical activity and central nervous system metabolic signaling. These preclinical and biomarker-level findings collectively build a mechanistic case, but the pathway specificity and population boundaries remain insufficiently defined for confident translation.

Several pervasive methodological questions limit the interpretive confidence of the Exercise Effects evidence base and define the primary challenges for future research. First, the choice and specification of endpoints remains inconsistent across the field: studies report functional measures (gait speed, grip strength, chair-rise time), biomarker panels (CRP, Klotho, myostatin, follistatin), imaging surrogates (muscle cross-sectional area), cognitive batteries, and hard clinical events, yet few trials are powered for the latter, and the degree to which surrogate endpoints predict clinical benefit is an unresolved concern (Ioannidis 2005). Second, the cross-study disagreement map reveals that the most severely contested outcome classes are not those with the sparsest data but rather those with the most conflicting signals — for example, the immune inflammation domain shows a severity-5 disagreement (Ye 2024 vs Wei 2025), and the frailty domain shows a severity-5 disagreement between Wan 2025 and Wu 2026, suggesting that the direction and magnitude of exercise effects may be critically population-dependent rather than universal. Third, the concurrent intervention problem is pervasive: numerous trials combine exercise with protein supplementation (Jeong 2026; Liao 2019), essential amino acids (Thavonlun 2026), nutritional counseling (Sharna 2026), or pharmacological agents (Stanfield 2026), making it difficult to isolate the independent contribution of Exercise Effects per se. Sixth, attrition in long-duration RCTs of older adults typically approximates 20% (Schulz 2010), and adherence data from the present corpus confirm this pattern, with the Tait 2026 trial reporting roughly 40% adherence at later time points. Across the corpus, these methodological considerations suggest that while the Exercise Effects anti-aging case is mechanistically compelling and broadly supported by functional and biomarker endpoints, its translation to hard clinical outcomes and its generalizability across diverse older adult populations remain incomplete and demand more rigorous, longer-duration, adequately powered clinical trials with standardized endpoints.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-exercise_effects-v06-DAILY-2026-06-07T12-08-38Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-07.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• exercise effects aging
• exercise effects older adults
• exercise effects randomized controlled trial
• exercise aging
• exercise older adults
• exercise randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses exercise effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 205 records in the receipt-candidate union, 85 were classified as source candidates and 78 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	205
Classified source candidates	85
No extractable claims	13
None-only claim binding	2
Mixed partial-or-none claim-binding candidates	62
Partial-only claim-binding candidates	10
Strict high-confidence sources	33
Admitted final sources	78

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune, immune and inflammation, muscle function, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=44; claims=2217	no extracted directional signal in 22/44 sources	4 direct; 10 indirect; 30 review	limited corpus depth in this outcome class
Muscle Function	n=8; claims=567	unclear signal in 4/8 sources	2 indirect; 6 review	limited corpus depth in this outcome class
Cardiometabolic	n=7; claims=357	no extracted directional signal in 4/7 sources	1 direct; 6 review	limited corpus depth in this outcome class
Frailty	n=6; claims=428	no extracted directional signal in 2/6 sources	1 direct; 1 indirect; 4 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=4; claims=187	no extracted directional signal in 2/4 sources	1 direct; 3 review	limited corpus depth in this outcome class
Immune	n=4; claims=123	no extracted directional signal in 2/4 sources	4 review	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=192	positive signal in 1/2 sources	1 direct; 1 review	limited corpus depth in this outcome class
Cognitive	n=1; claims=33	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Population / prevalence	n=1; claims=30	unclear signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=80	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating

Results Summary

• Contextual Adjacent Evidence: n=44; claims=2217; no extracted directional signal in 22/44 sources | directness: 4 direct; 10 indirect; 30 review; main limitation: directionally heterogeneous.
• Muscle Function: n=8; claims=567; mixed signal in 4/8 sources | directness: 2 indirect; 6 review; main limitation: no direct clinical anchor.
• Cardiometabolic: n=7; claims=357; no extracted directional signal in 4/7 sources | directness: 1 direct; 6 review; main limitation: directionally heterogeneous.
• Frailty: n=6; claims=428; no extracted directional signal in 2/6 sources | directness: 1 direct; 1 indirect; 4 review; main limitation: directionally heterogeneous.
• Dosing and Pharmacokinetics: n=4; claims=187; no extracted directional signal in 2/4 sources | directness: 1 direct; 3 review; main limitation: directionally heterogeneous.
• Immune: n=4; claims=123; no extracted directional signal in 2/4 sources | directness: 4 review; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

Tariq 2026 found that chronotype-aligned exercise led to significantly greater improvements in systolic BP (-10.8 vs -5.5 mm Hg, P = 0.002), diastolic BP, RMSSD, VO₂ peak, LDL, fasting glucose, and PSQI scores compared to controls.

Mechanistically, the cardiometabolic benefits observed likely involve multiple pathways. Tai Chi, a mind-body exercise, may improve cardiovascular function through enhanced autonomic regulation and stress reduction, as evidenced by the significant blood pressure reductions reported by Liu 2026. Chronotype-aligned exercise, as studied by Tariq 2026, may optimize circadian rhythm alignment, potentially improving metabolic regulation and cardiovascular function. Isometric handgrip exercise, per Champaiboon 2026, likely induces shear stress-mediated vascular adaptations. The meta-analytic findings from Gong 2026 and Li 2026b suggest that exercise improves body composition and metabolic parameters through increased energy expenditure and muscle-mediated glucose uptake.

Within the corpus, tensions exist regarding the magnitude and consistency of cardiometabolic effects. While Tariq 2026 and Champaiboon 2026 reported significant positive effects on blood pressure and other cardiometabolic markers, the systematic reviews by Yu 2026 and Cares 2026 provided less clear conclusions. Yu 2026 found that for BMI, only multicomponent training significantly reduced BMI compared to usual care, suggesting exercise modality matters. Cares 2026's review of diet and exercise in pediatric cancer survivors highlighted heterogeneous study designs and outcomes, making definitive conclusions challenging. This variability underscores the importance of considering exercise modality, population, and intervention specifics when interpreting cardiometabolic outcomes.

Cognitive Outcomes

The COPE-iOS study represents a rigorously designed randomised controlled trial protocol targeting cognitive and functional outcomes in older adults undergoing major surgery (Rengel 2026). This trial examines the efficacy of a combined cognitive and physical exercise programme performed both preoperatively and postoperatively. The study population comprises older adults—a demographic particularly vulnerable to postoperative cognitive dysfunction—and the intervention integrates both cognitive and physical exercise modalities to address this clinical challenge. The protocol specifies cognitive and functional improvement as primary endpoints, with the dual-exercise approach reflecting emerging evidence that multimodal interventions may yield additive or synergistic benefits over single-domain exercise programmes.

Quantitative findings from the COPE-iOS trial remain unavailable as the protocol describes the study design rather than reporting outcome data (Rengel 2026). The absence of effect sizes, p-values, or sample size estimates in the available source reflects the pre-results stage of this trial. Consequently, the magnitude and statistical significance of combined cognitive-physical exercise on postoperative cognitive trajectories in older adults cannot yet be determined from this evidence source. Future publication of the completed trial results will be essential for quantifying the intervention effect and informing clinical practice regarding prehabilitation strategies.

Mechanistically, the rationale for combining cognitive and physical exercise rests on complementary neurobiological pathways. Physical exercise promotes cerebrovascular health, neurotrophic factor expression, and neurogenesis, while cognitive training engages synaptic plasticity and cognitive reserve mechanisms (Rengel 2026). The COPE-iOS protocol implicitly invokes the hypothesis that these convergent pathways may produce additive neuroprotection in the perioperative setting, where surgical stress, anaesthesia, and inflammation converge to threaten cognitive integrity. Preclinical data suggest that exercise-induced upregulation of brain-derived neurotrophic factor (BDNF) and related signalling cascades supports neuronal survival under stress conditions, providing a mechanistic substrate for the clinical hypothesis being tested.

Within the curated corpus, the evidence base for exercise effects on cognitive outcomes presents a mixed profile. The COPE-iOS protocol contributes a well-structured framework for testing multimodal exercise in a surgical population, yet the absence of completed outcome data means the trial cannot currently adjudicate whether combined cognitive-physical exercise produces meaningful cognitive benefits in older adults (Rengel 2026). This stands in contrast to the broader literature, where positive signals for exercise on cognition coexist with null or inconsistent findings across different populations and intervention modalities. The synthesis highlights that mechanistic plausibility coexists with incomplete human-RCT evidence, and the boundary conditions—such as optimal exercise type, intensity, timing, and duration—remain to be established for cognitive outcomes specifically.

Contextual Adjacent Evidence Outcomes

The corpus encompasses a heterogeneous set of trials examining exercise across physical, cognitive, metabolic, and functional domains in older adults. Kulik 2026 randomized older adults with HIV to 16 weeks of high-intensity interval training (HIIT) or continuous moderate-intensity exercise (CME), both combined with resistance exercise.

Quantitative findings from meta-analytic syntheses consistently favor exercise interventions, though effect magnitudes vary by domain and modality.

Mechanistically, the functional benefits observed across these trials may be mediated through several converging pathways. Guldan 2026 reported that higher circulating α-Klotho levels were significantly associated with lower odds of frailty (P < 0.0001, P < 0.0001), linking the klotho axis to frailty outcomes. The study was assessor-blinded and stratified participants by nutritional status, enabling comparison of exercise responses in those with and without baseline deficiency. This design provides indirect evidence linking aerobic activity to changes in nutritional markers but does not establish causality. Sample size and specific deficiency endpoints are not reported in the available excerpts, limiting quantitative synthesis. The trial duration of 12 weeks is typical for exercise interventions targeting physiological adaptation.

Dosing and Pharmacokinetics Outcomes

The dosing and pharmacokinetic evidence base for exercise interventions in older adults is heterogeneous, drawing on one clinical RCT, two systematic reviews, and one observational cohort. The RCT by Qiu 2026 compared different Tai Chi styles versus traditional community-based exercises in middle-aged and older adults, focusing on cardiometabolic and physical function endpoints over the study duration. Feng 2024 conducted a systematic review and meta-analysis examining exercise with or without β-hydroxy-β-methylbutyrate (HMB) supplementation in frail or sarcopenic adult populations. Liu 2026b performed a systematic review and meta-analysis on astaxanthin supplementation and its effects on exercise recovery biomarkers and performance.

Quantitative findings across these studies were largely null for combined supplementation strategies. Feng 2024 similarly reported that for physical performance outcomes, the combined exercise-plus-HMB approach yielded non-significant results (P = 0.66, P = 0.78, P = 0.60). These findings are detailed in the evidence synthesis.

Mechanistically, the rationale for combining nutritional supplementation with exercise targets the mTOR signaling pathway to enhance muscle protein synthesis, yet the clinical RCT data from Thavonlun 2026 do not support additive benefits for appendicular skeletal muscle mass. The mechanistic substrate underlying the null findings may relate to insufficient dosing, duration, or the specific amino acid profiles used. Preclinical data from Liu 2026b suggest astaxanthin reduces creatine kinase levels as a recovery biomarker (SMD reported), but the clinical translation of this finding remains unclear as the review did not find consistent exercise performance benefits. The Tai Chi findings from Qiu 2026 demonstrate that exercise modality itself, rather than exogenous supplementation, may drive cardiometabolic dose-responses.

Frailty Outcomes

Quantitative findings across the corpus present a complex and often contradictory picture. Zhu 2025 similarly reported significant effects for exercise on physical function in nursing home residents (P < 0.001). Hong 2026 reported significant reductions in physical frailty in the intervention group compared to usual care (P = 0.002, P = 0.015), yet this was characterized as a null overall effect.

Mechanistically, the positive findings from Wan 2025 and Zhu 2025 align with the rationale that exercise can attenuate sarcopenia-related muscle loss and improve neuromuscular function. The multicomponent approach used by Hong 2026, targeting physical, cognitive, and psychological domains, reflects a broader understanding of frailty as a multidimensional syndrome. Preclinical data suggest that exercise activates molecular pathways such as mTOR and AMPK, which regulate muscle protein synthesis and mitochondrial biogenesis. However, the clinical translation of these pathways appears inconsistent, as the negative findings from Wu 2026 on the Otago program in sarcopenia highlight.

Significant tensions exist within the corpus regarding the efficacy of exercise for frailty. Wan 2025 (positive) and Wu 2026 (negative) present a direct disagreement on the effectiveness of exercise-based programs in older adults with sarcopenia. Similarly, Zhu 2025 (mixed) and Wu 2026 (negative) disagree on the utility of exercise interventions for frail older adults. Shen 2023, with an unclear effect direction, contrasts with the null findings reported by Hong 2026 and the protocol described by Zou 2026, which focuses on intervention preferences rather than outcomes. The agreement between Zou 2026 and Hong 2026 on null or unspecified effects further complicates the evidence synthesis, suggesting that the benefits of exercise for frailty may be highly contingent on the specific intervention, population, and outcome measure.

Immune Outcomes

The corpus includes four synthesized references addressing exercise effects on inflammatory and immune biomarkers in adult populations. Huang 2026 reports a Bayesian network meta-analysis in postmenopausal obesity examining modality-specific immunometabolic effects. Jamrasi 2025 presents a 12-week RCT evaluating Meteorin-like (Metrnl) levels and inflammatory markers in community-dwelling older adults, while Cao 2026 provides a network meta-analysis of combined exercise and nutritional interventions in sarcopenic populations. Together, these sources span meta-analytic, RCT, and mechanistic evidence streams.

Quantitative findings across these sources reveal heterogeneous effects on inflammatory endpoints. Full per-study endpoint details are presented in the evidence synthesis.

Mechanistically, the anti-inflammatory action of exercise appears to operate through multiple converging pathways. Huang 2026 highlights modality-specific immunometabolic regulation in postmenopausal obesity, suggesting that resistance training may engage skeletal-muscle-driven anti-inflammatory signaling more robustly than aerobic modalities. Jamrasi 2025 implicates Meteorin-like protein — a myokine released during exercise — as a mediator linking physical activity to reduced systemic inflammation in older adults. Preclinical data reviewed in Cao 2026 suggest that aerobic exercise attenuates inflammatory cascades in sarcopenic muscle, complementing the clinical RCT evidence of functional improvement. The mechanistic substrate underlying these findings involves myokine secretion, reduced visceral adiposity, and improved insulin sensitivity, all of which converge on NF-κB and related inflammatory transcriptional pathways.

Within the corpus, a notable tension exists between the largely positive meta-analytic signal in Chu 2026 and the more heterogeneous findings reported by Jamrasi 2025, where several inflammatory biomarkers did not achieve statistical significance despite functional improvements. These discrepancies likely reflect differences in population characteristics, exercise prescription parameters, and the specific biomarkers assessed rather than a fundamental contradiction in the underlying biology. The evidence as a whole supports a context-dependent anti-inflammatory effect of exercise, with the strongest signals emerging from resistance training in metabolically compromised populations.

Immune and Inflammation Outcomes

In the meta-analysis by Wei 2025, exercise significantly reduced body mass index (MD = -1.35, P < 0.0001), with further improvements noted in other body composition and inflammatory parameters reaching significance at P < 0.001 and P < 0.00001 thresholds across pooled estimates (the evidence synthesis). Ye 2024 reported that 24 weeks of Baduanjin exercise increased MoCA scores by 2.51 ± 0.32 points (P < 0.001) and decreased frailty scores, with additional biomarker improvements in oxidative stress and inflammation reaching significance at P < 0.05 and P = 0.012 levels (the evidence synthesis). Collectively, these findings indicate that structured exercise produces statistically significant reductions in inflammatory burden and improvements in functional cognition among older adults.

Mechanistically, the reductions in inflammatory markers observed in both Wei 2025 and Ye 2024 are consistent with the known anti-inflammatory effects of regular physical activity, including downregulation of pro-inflammatory cytokines and modulation of oxidative stress pathways. The Baduanjin intervention studied by Ye 2024 specifically targets mind-body coordination and may attenuate chronic low-grade inflammation through neuroendocrine-immune crosstalk, providing a plausible mechanistic substrate for the cognitive and frailty improvements reported. These clinical findings align with broader preclinical and mechanistic evidence that exercise activates adaptive stress responses and enhances immune surveillance.

By contrast, the direction of evidence differs between these two sources. Wei 2025 synthesizing multiple trials in sarcopenic obesity populations reports consistently positive effects of exercise on inflammatory and body composition outcomes, whereas Ye 2024, while demonstrating significant biomarker improvements, enrolled a distinct population with cognitive frailty and used a specific mind-body exercise modality rather than conventional aerobic or resistance training. This contextual divergence suggests that the anti-inflammatory efficacy of exercise may depend on baseline disease phenotype, exercise modality, and intervention duration, highlighting the need for further RCT evidence across diverse older adult populations.

Muscle Function Outcomes

Quantitative findings from the meta-analytic sources consistently report statistically significant benefits of exercise on key muscle function endpoints. Liao 2019 demonstrated that combined protein supplementation and exercise therapy significantly improved whole-body lean mass in older adults with sarcopenia (P < 0.00001). Furthermore, Li 2026c found that exercise based on wearable electronic devices significantly improved lower limb strength and balance in older adults (P < 0.001). A mechanistic review by Oliveira 2026 also identified a significant increase in plasma soluble Klotho levels following acute aerobic exercise (SMD 0.69; 95%CI 0.41-0.97; P < 0.0001), suggesting a potential anti-aging biomarker pathway.

Mechanistically, the benefits of exercise on muscle function are supported by several converging pathways evident in this corpus. Preclinical and human data suggest that exercise stimulates muscle protein synthesis, mitigates disuse-induced atrophy, and may influence longevity-related biomarkers. The integration of nutritional support with exercise, as examined by Liao 2019, appears to synergistically enhance lean mass gain, pointing to the importance of combined anabolic stimuli. Lin 2026 further explores this multimodal approach, investigating the optimal combination of protein sources and exercise modalities for older adults. The protocol by Alawadhi 2026 aims to test whether structured resistance exercise can preserve lean mass during semaglutide or tirzepatide therapy, directly addressing a contemporary clinical concern about pharmacologically-induced muscle loss.

Despite widespread agreement on the general efficacy of exercise, important tensions exist within the corpus regarding effect consistency and specificity. Xiong 2025 reports an unclear overall effect direction for exercise on muscle function in the context of sleep quality improvement, contrasting with the more definitively positive or mixed signals reported by Padilha 2026 and Wang 2022 for direct strength and mass outcomes. Li 2026c, while reporting a negative overall effect direction, still found significant benefits for lower limb strength when exercise was guided by wearable devices, creating a nuanced picture that differs from the uniformly positive findings of Padilha 2026. These disagreements likely stem from heterogeneity in intervention modalities (e.g., aerobic vs. resistance vs. combined), population characteristics (e.g., sarcopenia severity, hospitalization status), and the specific endpoints measured, underscoring the need for precise exercise prescription.

Skeletal, Fracture, and Bone Outcomes

The INVEST in bone health RCT (Lynch 2026), a clinical RCT, enrolled older adults participating in a weight loss intervention with secondary analysis of bone and muscle outcomes. Participants achieved similar and significant weight loss of approximately 10% across all study groups. At 12-month follow-up, the group combining weight loss with resistance training (WL + RT) demonstrated an increase in mid-thigh muscle cross-sectional area of 0.5% (P < 0.05) compared to control conditions. This finding suggests that resistance training can partially counteract the muscle loss typically associated with caloric restriction in older populations.

Secondary bone-related findings from the INVEST trial showed a range of statistical signals across multiple endpoints. Several outcomes reached statistical significance at conventional thresholds, with p-values reported as P < 0.05, P < 0.03, and P < 0.001 for various bone density and turnover markers. The full per-study endpoint evidence is detailed in the evidence synthesis.

Mechanistically, resistance exercise is hypothesized to preserve bone mineral density through mechanical loading and muscle-bone crosstalk pathways. The 0.5% increase in mid-thigh muscle CSA observed in the WL + RT group provides a plausible substrate for improved skeletal loading during functional activities. Weighted vest use, another intervention arm in this trial, aims to simulate gravitational loading on the skeleton, though the available source data focus primarily on the resistance training comparison. These mechanistic pathways align with broader preclinical data suggesting that osteocyte mechanotransduction mediates bone adaptation to physical stress.

By contrast, the pattern of mixed statistical signals within a single trial underscores the heterogeneity of exercise effects on skeletal outcomes. The coexistence of significant findings (P < 0.001) with borderline null results (P = 0.08) from the same study population suggests that exercise benefits for bone health are not uniform across all skeletal endpoints. The 12-month duration of the INVEST trial may be insufficient to detect robust bone mineral density changes, as bone remodeling cycles operate on longer timescales. This tension between positive muscle outcomes and variable bone findings highlights the need for longer-duration trials with site-specific bone density endpoints.

Population / prevalence Outcomes

Quantitative findings from Yang 2026 are incomplete in the curated excerpts. The authors report both significant (P < 0.05) and non-significant (P > 0.05) findings across measured outcomes, though the specific endpoints corresponding to each p-value threshold are not delineated. This mixed pattern of statistical significance suggests that the intervention produced heterogeneous effects depending on the nutritional subgroup or the specific biomarker assessed. Without access to full effect sizes, confidence intervals, or subgroup-specific p-values, the magnitude of exercise-related changes in deficiency prevalence cannot be determined from this source alone. The coexistence of positive and null findings within a single study underscores the need for targeted replication.

Mechanistically, aerobic exercise is known to modulate appetite-regulating hormones, improve gastrointestinal motility, and enhance nutrient absorption pathways, all of which could plausibly reduce deficiency prevalence in malnourished older adults. Preclinical data and smaller human studies have demonstrated exercise-induced upregulation of gut microbiota diversity, which Yang 2026 explicitly investigates in the context of octogenarian malnutrition. However, the clinical RCT evidence directly linking brisk walking to reversal of nutritional deficiency in this age group remains sparse. The observational cohort design of Yang 2026 cannot rule out confounding by concurrent nutritional support, baseline health status, or self-selection bias. Thus, while the mechanistic substrate is biologically plausible, the human evidence base is insufficient to confirm a causal exercise–deficiency link.

A notable tension within the deficiency prevalence literature is the discordance between positive and null statistical signals reported in Yang 2026 itself. Some measured outcomes achieved conventional significance (P < 0.05) while others did not (P > 0.05), yet the curated excerpts do not specify which outcomes fell into each category. This internal heterogeneity prevents a clear conclusion about whether exercise reliably reduces deficiency prevalence in malnourished octogenarians. By contrast, the broader Exercise Effects corpus includes robust evidence in other outcome classes, such as frailty, suggesting that deficiency prevalence may represent a boundary condition where exercise benefits are attenuated. The absence of additional cohort studies or RCTs in this outcome class further limits the ability to resolve this tension through meta-analytic pooling.

Population / prevalence remains a separate Results slice (n=1; claims=30; unclear signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Cross-Domain Synthesis

Cross-domain interpretation of exercise effects is constrained by the relationship between clinical sources (Tait 2026, Qiu 2026, Stanfield 2026) and mechanistic studies (the retained evidence base). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.

The main cross-domain pattern is the coexistence of positive signals in the contextual adjacent evidence, frailty, immune and inflammation outcome classes with null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes and negative signals in the contextual adjacent evidence, frailty, immune and inflammation outcome classes. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.

923 cross-study disagreements prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Load-Bearing Tensions

• Tait 2026 versus Huang 2026b defines a Contextual Adjacent Evidence disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.
• Kulik 2026 versus Tait 2026 defines a Contextual Adjacent Evidence disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.
• Tait 2026 versus Stene 2026 defines a Contextual Adjacent Evidence disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.
• Malin 2026 versus Huang 2026b defines a Contextual Adjacent Evidence disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.
• Ye 2024 versus Wei 2025 defines a Immune and Inflammation disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 78 curated reference papers, the evidence base for Exercise Effects shows a context-dependent profile. Positive signals appear in: contextual other, frailty. Negative signals appear in: contextual other, frailty. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Exercise Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 78 included sources. The evidence-tier distribution is: B2 (n=51), B1 (n=19), A1 (n=8). By directness, the breakdown is: review (n=56), indirect (n=14), direct (n=8). 59 of 78 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: type 2 diabetes patients; adults; older adults; frail / sarcopenic adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by systematic reviews and meta-analyses rather than primary long-duration randomized controlled trials, which constrains causal inference for most endpoints. For example, the most robust signals for sarcopenia outcomes (Shen 2023) and cardiovascular markers (Shen 2026) derive from review-level evidence pooling heterogeneous interventions rather than from individually powered RCTs. No long-term mortality trial or hard clinical-event endpoint trial (e.g., incident fracture, hospitalization, cardiovascular death) was represented in this corpus, leaving the headline conclusions reliant on functional and biomarker surrogates. This absence is significant because surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005), and the gap between mechanistic improvement and event-rate reduction remains unresolved.

Several outcome classes are anchored to a single study, precluding internal replication within the corpus. The dose–response relationship for Tai Chi on cardiometabolic health rests solely on Qiu 2026, while the effects of electroacupuncture combined with the Otago Exercise Program on sarcopenia are reported only by Wu 2026. Similarly, the immunometabolic effects of exercise in postmenopausal obesity are traced to a single Bayesian network meta-analysis (Huang 2026), and the impact of vitamin K₂ on muscle-damaging resistance exercise recovery comes from one RCT (Lithgow 2026). Without independent corroboration from a second source, these findings cannot be distinguished from study-specific artifacts, sample-size effects, or population idiosyncrasies.

The enrolled populations are overwhelmingly older adults, frequently from East Asian settings practicing Tai Chi or Baduanjin (Liu 2026; Ye 2024; Hu 2025), or Western cohorts of community-dwelling elderly women (Shen 2026). This geographic and demographic narrowness limits external validity to younger adults, non-ambulatory individuals, and populations outside high-income Asian and European/North American healthcare systems. The synthesis therefore cannot establish whether observed exercise effects generalize to younger, more ethnically diverse, or resource-limited populations where sarcopenia and frailty prevalence is also rising.

The corpus is strong on functional and biomarker endpoints—gait speed, grip strength, inflammatory cytokines, body composition—but critically sparse on clinically definitive endpoints. Furthermore, the mechanistic bridge from biomarkers such as circulating s-Klotho (Oliveira 2026: SMD 0.69, 95% CI 0.41–0.97 for acute aerobic exercise) to clinically meaningful outcomes like reduced frailty transitions has not been established in any trial within the corpus, leaving a substantial mechanism-to-clinic gap that limits translational confidence.

Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

Bounded conclusion

This synthesis supports a bounded interpretation across 78 included sources. The evidence tiers are B2 (n=51), B1 (n=19), A1 (n=8), and directness is review (n=56), indirect (n=14), direct (n=8). These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The practical result is therefore conservative. Positive or negative signals should be read only inside the populations, outcome classes, follow-up windows, and evidence tiers represented in the included sources. Null and mixed findings remain part of the conclusion because they mark boundary conditions rather than noise. The next useful study is the one that resolves those boundaries with direct, clinically proximate endpoints and source-traceable measurements. Until that evidence exists, the most reproducible conclusion is the evidence map itself: what is directly supported, what remains mechanistic or indirect, and which uncertainties should control future inference.

This closing statement is intentionally limited to corpus structure. It does not add a new treatment claim, safety claim, mechanism claim, or pooled estimate. It records the inference boundary that follows from the included sources: stronger conclusions require aligned direct evidence, clinically meaningful endpoints, and fewer unresolved contradictions; weaker or indirect findings remain useful for hypothesis generation and study design. That boundary keeps the paper publishable without converting a broad, uneven literature into stronger advice than the source record can support.

What This Synthesis Adds

This synthesis maps 78 included sources on Exercise Effects across 10 outcome classes and 923 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

The strongest unresolved contrast is the disagreement between Ye 2024 and Wei 2025 on immune and inflammation (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Shen 2026, Oliveira 2026, Wei 2025, Zhu 2025, Wang 2026) emphasize convergent signals on Exercise Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
muscle function	0	8	mixed, negative, null, unclear	conflict-resolution gap
immune	0	4	negative, null, unclear	direct interventional hard-endpoint gap
cognitive	0	1	null	direct interventional hard-endpoint gap
cardiometabolic	1	6	null, positive, unclear	replication gap
frailty	1	5	mixed, negative, null, positive, unclear	conflict-resolution gap
deficiency prevalence	0	1	unclear	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	4	40	mixed, negative, null, positive, unclear	conflict-resolution gap
dosing and pharmacokinetics	1	3	negative, null, unclear	replication gap
immune and inflammation	1	1	negative, positive	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	muscle function: conflict-resolution gap	0 direct and 8 indirect sources; direction profile: mixed, negative, null, unclear
P2	immune: direct interventional hard-endpoint gap	0 direct and 4 indirect sources; direction profile: negative, null, unclear
P3	cognitive: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P4	cardiometabolic: replication gap	1 direct and 6 indirect sources; direction profile: null, positive, unclear
P5	frailty: conflict-resolution gap	1 direct and 5 indirect sources; direction profile: mixed, negative, null, positive, unclear

Next-Study Design Recommendation

The next high-yield study for Exercise Effects should target the muscle function evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Tait 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=negative; representative statistic=P = 0.008.
• Qiu 2026; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.002.
• Stanfield 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.007.
• Champaiboon 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.011.
• Ye 2024; tier=A1; directness=direct; endpoint=immune inflammation; direction=negative; representative statistic=P < 0.001.
• Lithgow 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.431.
• Hong 2026; tier=A1; directness=direct; endpoint=frailty; direction=null; representative statistic=P < 0.001.
• Huang 2026b; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P = 0.02.
• Shen 2026; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.00001.
• Oliveira 2026; tier=B1; directness=review; endpoint=muscle function; direction=unclear; representative statistic=P < 0.00001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 5 disagreement: Ye 2024 vs Wei 2025; Ye 2024 (negative) vs Wei 2025 (positive) on immune inflammation
• Severity 5 disagreement: Wan 2025 vs Wu 2026; Wan 2025 (positive) vs Wu 2026 (negative) on frailty
• Severity 5 disagreement: Kulik 2026 vs Tait 2026; Kulik 2026 (positive) vs Tait 2026 (negative) on contextual other
• Severity 5 disagreement: Kulik 2026 vs Malin 2026; Kulik 2026 (positive) vs Malin 2026 (negative) on contextual other
• Severity 5 disagreement: Tait 2026 vs Jeong 2026; Tait 2026 (negative) vs Jeong 2026 (positive) on contextual other
• Severity 5 disagreement: Tait 2026 vs Huang 2026b; Tait 2026 (negative) vs Huang 2026b (positive) on contextual other
• Severity 5 disagreement: Tait 2026 vs Stene 2026; Tait 2026 (negative) vs Stene 2026 (positive) on contextual other
• Severity 5 disagreement: Tait 2026 vs Wang 2026; Tait 2026 (negative) vs Wang 2026 (positive) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Kulik 2026b, Hu 2026, Liu 2025, Chen 2026, Asteasu 2024, Wang 2026b, Geng 2026, Li 2026, Sadjapong 2020, Wen 2026, Shao 2026, Xu 2026, Lee 2026, Kim 2025, Ma 2026, Zhang 2026, Etayo-Urtasun 2025, Jiawei 2026, Kunitake 2026, Deng 2026, Wu 2025, Zanotto 2026, Sanchez-Martinez 2026, Zhang 2026b, Saxton 2026, Papaioannou 2026, Cruz-Lopez 2026, Wimo 2026, Azanon-Nogueira 2026, Paz-Monton 2026, Nystoriak 2018, Studenski 2011, Cesari 2009, Bohannon 1997, Tinetti 1988.

References

• Shen 2026. Effects of exercise on metabolic risk, cardiovascular fitness, and body composition in elderly women of the past decade: a systematic review and meta-analysis. Journal of the International Society of Sports Nutrition, 2026. DOI: 10.1080/15502783.2026.2675444. PMID: 42228407.
• Wan 2025. Effectiveness of Mind–Body Exercise in Older Adults With Sarcopenia and Frailty: A Systematic Review and Meta‐Analysis. Journal of Cachexia, Sarcopenia and Muscle, 2025. DOI: 10.1002/jcsm.13806. PMID: 40254030.
• Oliveira 2026. Effects of acute, subacute, and chronic exercise on plasma s-Klotho levels: a systematic review and meta-analysis. Journal of Physiology and Biochemistry, 2026. DOI: 10.1007/s13105-026-01182-2. PMID: 42067671.
• Padilha 2026. Disuse‐Induced Muscle Atrophy and Muscle Weakness From Hospitalization to Spaceflight: Exercise Succeeds in Prevention and Treatment—A Meta‐Analysis. Journal of Cachexia, Sarcopenia and Muscle, 2026. DOI: 10.1002/jcsm.70259. PMID: 41983453.
• Wei 2025. Exercise interventions of ≥8 weeks improve body composition, physical function, metabolism, and inflammation in older adults with stage I sarcopenic obesity: a systematic review and meta-analysis. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1575580. PMID: 40873450.
• Tait 2026. Can dual-task high-velocity exercise training improve cognitive function in older adults? Secondary analysis of an 18-month cluster randomized controlled trial. Age and Ageing, 2026. DOI: 10.1093/ageing/afaf385. PMID: 41575070.
• Liu 2026. A systematic review and meta-analysis of the mechanism of action of Tai Chi on cardiovascular disease: evidence map of aerobic and mind-body exercise pathways. Scientific Reports, 2026. DOI: 10.1038/s41598-026-35996-3. PMID: 41617914.
• Guldan 2026. Circulating α-Klotho and Multidimensional Aging and Frailty Outcomes: A Systematic Review and Meta-Analysis from the European Renal Association CKD-MBD Working Group. Calcified Tissue International, 2026. DOI: 10.1007/s00223-026-01537-3. PMID: 42060134.
• Stene 2026. Effects of 5 Years of Aerobic Exercise on Sarcopenia in Older Adults—Secondary Outcomes of the Generation 100 Study. Journal of Cachexia, Sarcopenia and Muscle, 2026. DOI: 10.1002/jcsm.70279. PMID: 41936539.
• Zhu 2025. Effects of exercise interventions on physical function, cognitive function and quality of life of frail older adults in nursing homes: a systematic review and meta-analysis. Frontiers in Psychology, 2025. DOI: 10.3389/fpsyg.2025.1679734. PMID: 40978256.
• Qiu 2026. Dose-Related Effects of Different Tai Chi Styles Versus Traditional Community-Based Exercises on Cardiometabolic Health and Physical Function in Middle-Aged and Older Adults: Randomized Controlled Trial. JMIR Aging, 2026. DOI: 10.2196/80125. PMID: 42061844.
• Kulik 2026. Comparing the Effectiveness of High Intensity Interval Training vs Continuous Moderate Intensity Exercise on Physical Function Among Older Adults With HIV. Open Forum Infectious Diseases, 2026. DOI: 10.1093/ofid/ofag002. PMID: 41583703.
• Wu 2026. The effects of electroacupuncture and the Otago Exercise Program in older adults with sarcopenia: A randomized controlled study. Medicine, 2026. DOI: 10.1097/MD.0000000000049033. PMID: 42175481.
• Kulik 2026b. The effects of high-intensity interval training versus continuous moderate-intensity exercise on body composition among older adults with HIV. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2026. DOI: 10.1093/gerona/glag113. PMID: 42080214.
• Lynch 2026. Weighted vest use or resistance exercise to offset muscle loss in older adults: secondary findings from the INVEST in bone health RCT. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2026. DOI: 10.1093/gerona/glag062. PMID: 41761582.
• Stanfield 2026. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. Journal of Cachexia, Sarcopenia and Muscle, 2026. DOI: 10.1002/jcsm.70274. PMID: 41985884.
• Hu 2026. Can exercise combined with transcranial direct current stimulation improve cognitive function in older adults? A systematic review and meta-analysis. Frontiers in Neuroscience, 2026. DOI: 10.3389/fnins.2026.1836124. PMID: 42182054.
• Wang 2026. Effects of Digital-Based Exercise Interventions on Concerns About Falling, Falls Efficacy, and Physical Performance Among Older Adults: Systematic Review and Meta-Analysis. JMIR Aging, 2026. DOI: 10.2196/87070. PMID: 42060908.
• Liu 2025. Meta-analysis of the effects of multi-component exercise on cognitive function in older adults with cognitive impairment. Frontiers in Aging Neuroscience, 2025. DOI: 10.3389/fnagi.2025.1551877. PMID: 40297493.
• Tariq 2026. Chronotype-aligned exercise timing in middle-aged adults at cardiometabolic risk: a randomised controlled trial. Open Heart, 2026. DOI: 10.1136/openhrt-2025-003573. PMID: 41980852.
• Chen 2026. Exercise-induced changes in systemic inflammatory biomarkers in overweight and obese populations: a bibliometric analysis and umbrella review of meta-analyses. Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1838118. PMID: 42245630.
• Xiong 2025. Optimal exercise type and dose to improve sleep quality in older adults: a systematic review and network meta-analysis. BMC Geriatrics, 2025. DOI: 10.1186/s12877-025-06607-z. PMID: 41316008.
• Champaiboon 2026. Effect of home-based isometric handgrip exercise with a commercially available device on blood pressure in older adults with hypertension: A randomized controlled trial. PLOS One, 2026. DOI: 10.1371/journal.pone.0342563. PMID: 41779689.
• Ye 2024. Effects of Baduanjin exercise on cognitive frailty, oxidative stress, and chronic inflammation in older adults with cognitive frailty: a randomized controlled trial. Frontiers in Public Health, 2024. DOI: 10.3389/fpubh.2024.1385542. PMID: 38846613.
• Asteasu 2024. Short‐Term Multicomponent Exercise Impact on Muscle Function and Structure in Hospitalized Older at Risk of Acute Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 2024. DOI: 10.1002/jcsm.13602. PMID: 39400535.
• Jeong 2026. Combined resistance exercise and essential amino acid intake enhance follistatin/myostatin ratio and muscle fitness in older women: a randomized controlled trial. Journal of the International Society of Sports Nutrition, 2026. DOI: 10.1080/15502783.2026.2646626. PMID: 41863133.
• Shen 2023. Exercise for sarcopenia in older people: A systematic review and network meta‐analysis. Journal of Cachexia, Sarcopenia and Muscle, 2023. DOI: 10.1002/jcsm.13225. PMID: 37057640.
• Wang 2026b. The effects of structured aerobic exercise and mind–body exercise on cognitive function in older adults with MCI: Systematic review and meta-analysis. Medicine, 2026. DOI: 10.1097/MD.0000000000047633. PMID: 41790706.
• Lin 2026. Explore the Optimal Treatment Regimen Across Combinations of Variate Protein Sources and Exercise Modalities and Its Associated Factors in Older Adults: A Network Meta-Analysis and Meta-Regression of Randomized Controlled Trials. Nutrients, 2026. DOI: 10.3390/nu18091409. PMID: 42124009.
• Chu 2026. Effects of exercise interventions on inflammatory biomarker levels in older adults with frailty and/or sarcopenia: a systematic review and meta-analysis. Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1734359. PMID: 42148069.
• Geng 2026. Psychological health outcomes of traditional Chinese exercises in older adults: a meta-analysis of randomized controlled trials. PeerJ, 2026. DOI: 10.7717/peerj.20773. PMID: 41695691.
• Li 2026. Effects of exercise training on depression, anxiety, and physical health-related quality of life in end-stage renal disease patients receiving maintenance hemodialysis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1788845. PMID: 42110291.
• Sadjapong 2020. Multicomponent Exercise Program Reduces Frailty and Inflammatory Biomarkers and Improves Physical Performance in Community-Dwelling Older Adults: A Randomized Controlled Trial. International Journal of Environmental Research and Public Health, 2020. DOI: 10.3390/ijerph17113760. PMID: 32466446.
• Jamrasi 2025. Effects of 12-week exercise on Meteorin-like levels, inflammation, and functional capacity in older adults: Korean national aging project randomized controlled study. European Geriatric Medicine, 2025. DOI: 10.1007/s41999-025-01272-2. PMID: 40699540.
• Wen 2026. Wuqinxi exercise for mind and balance: Enhancing cognition, fall prevention, and quality of life in older adults with mild cognitive impairment. PLOS One, 2026. DOI: 10.1371/journal.pone.0346490. PMID: 42090476.
• Shao 2026. Effects of exercise interventions on cognitive function in sedentary adults: a systematic review and network meta-analysis. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1794345. PMID: 42221635.
• Liao 2019. The Role of Muscle Mass Gain Following Protein Supplementation Plus Exercise Therapy in Older Adults with Sarcopenia and Frailty Risks: A Systematic Review and Meta-Regression Analysis of Randomized Trials. Nutrients, 2019. DOI: 10.3390/nu11081713. PMID: 31349606.
• Malin 2026. A Single Bout of Aerobic Exercise Increases Neuronal Extracellular Vesicle‐Derived Insulin Signaling Biomarkers in Adults With Cardiometabolic Risk. Comprehensive Physiology, 2026. DOI: 10.1002/cph4.70131. PMID: 41876945.
• Xu 2026. Effects of exercise on cognitive function in older patients with Alzheimer’s disease: a meta-regression and meta-analysis. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1793973. PMID: 42027916.
• Lee 2026. Effects of a postural balance apparatus–assisted combined exercise program on fall-related physical fitness and blood vessel elasticity among older women. Medicine, 2026. DOI: 10.1097/MD.0000000000048802. PMID: 42152327.
• Kim 2025. Effects of Integrating Wearable Activity Trackers With a Home-Based Multicomponent Exercise Intervention on Fall-Related Parameters and Physical Function in Older Adults: Randomized Controlled Trial. JMIR mHealth and uHealth, 2025. DOI: 10.2196/64458. PMID: 40340847.
• Ma 2026. The effectiveness of exercise interventions on muscle strength and balance function in pre-frail older adults: a systematic review and Bayesian network meta-analysis. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2025.1718120. PMID: 41675088.
• Feng 2024. Effects of exercise with or without β -hydroxy-β -methylbutyrate supplementation on muscle mass, muscle strength, and physical performance in patients with sarcopenia: a systematic review and meta-analysis. Frontiers in Nutrition, 2024. DOI: 10.3389/fnut.2024.1460133. PMID: 39360288.
• Wang 2022. Efficacy of Exercise on Muscle Function and Physical Performance in Older Adults with Sarcopenia: An Updated Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2022. DOI: 10.3390/ijerph19138212. PMID: 35805870.
• Zhang 2026. Effectiveness of exercise snacks on physical function: a systematic reviews with meta-analysis of randomized controlled trials. The Journal of Nutrition, Health & Aging, 2026. DOI: 10.1016/j.jnha.2026.100837. PMID: 41950555.
• Yu 2026. Comparative effectiveness of exercise modalities and nutritional supplementation for sarcopenic obesity in older adults: a network meta-analysis based on randomized controlled trials. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1775783. PMID: 41810309.
• Etayo-Urtasun 2025. Effects of Exercise on Autonomic Cardiovascular Function in Older Adults: A Systematic Review and Meta-Analysis. Sports Medicine (Auckland, N.z.), 2025. DOI: 10.1007/s40279-025-02357-5. PMID: 41264119.
• Jiawei 2026. Effect of Baduanjin Exercise and Resistance Band Training on Sarcopenia in the Elderly: A Randomized Controlled Trial. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2026. DOI: 10.12659/MSM.952000. PMID: 41858037.
• Cares 2026. Diet and Exercise Interventions in Pediatric Cancer Survivors and Effects on Cardiometabolic Disease Risk and Inflammaging Biomarkers: A Systematic Review. Advances in Nutrition, 2026. DOI: 10.1016/j.advnut.2026.100605. PMID: 41692128.
• Kunitake 2026. Effects of an exercise program using an smartphone App with remote or in-person supervision on the functional capacity of older adults: a randomized clinical. Einstein, 2026. DOI: 10.31744/einstein_journal/2026AO1757. PMID: 42018826.
• Deng 2026. Effectiveness of exercise intervention on muscle mass, muscle strength, and physical function among postmenopausal women with sarcopenia: a systematic review and meta-analysis. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1758325. PMID: 42245341.
• Wu 2025. A systematic review and meta-analysis of the effects of resistance exercise on cognitive function in older adults. Frontiers in Psychiatry, 2025. DOI: 10.3389/fpsyt.2025.1708244. PMID: 41503279.
• Rengel 2026. Cognitive and physical exercise to improve outcomes after surgery (COPE-iOS) study: protocol for a randomised, controlled trial in the USA examining the efficacy of a combined cognitive and physical exercise programme performed before and after major surgery in improving cognitive and functional outcomes for older adults. BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-110435. PMID: 41688121.
• Lithgow 2026. The effects of vitamin K 2 on recovery from muscle damaging resistance exercise in young and older adults – The TAKEOVER randomised controlled trial. Medicine and science in sports and exercise, 2026. DOI: 10.1249/MSS.0000000000003901. PMID: 41843412.
• Alawadhi 2026. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open, 2026. DOI: 10.1136/bmjopen-2026-116911. PMID: 42020128.
• Li 2026b. Effects of high-intensity interval training on glycemic control and cardiometabolic risk factors in adults with prediabetes: a systematic review and meta-analysis. Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1837386. PMID: 42222064.
• Hu 2025. Baduanjin exercise improves functional capacity and cardiovascular function in older adults with cardiovascular diseases: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2025.1419095. PMID: 40342973.
• Li 2026c. Effectiveness of exercise based on wearable electronic devices on lower limb strength and balance in older adults: a systematic review and meta-analysis. Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1778082. PMID: 41822921.
• Zanotto 2026. Reducing frailty in frail people with multiple sclerosis: Feasibility of a 6-week multimodal exercise training program. PLOS One, 2026. DOI: 10.1371/journal.pone.0347063. PMID: 41984883.
• Thavonlun 2026. Effect of leucine-enriched essential amino acid supplementation combined with different exercise regimen on appendicular skeletal muscle mass and muscle performance in older adults: an open label randomized controlled trial. JBMR Plus, 2026. DOI: 10.1093/jbmrpl/ziag052. PMID: 42038818.
• Sharna 2026. Effects of multimodal exercise programme combined with high-protein diet on glycaemic control in older adults with type 2 diabetes mellitus: study protocol for a randomised controlled trial. BMJ Open, 2026. DOI: 10.1136/bmjopen-2026-118313. PMID: 42134836.
• Yang 2026. Gut Microbiota Changes Following Aerobic Exercise in Malnourished Octogenarians: An Assessor-Blinded Intervention Study Stratified by Nutritional Status. Nutrients, 2026. DOI: 10.3390/nu18101627. PMID: 42197087.
• Liu 2026b. The Effects of Astaxanthin Supplementation on Exercise Recovery Biomarkers and Exercise Performance: A Systematic Review and Meta-Analysis. Nutrients, 2026. DOI: 10.3390/nu18101570. PMID: 42197030.
• Sanchez-Martinez 2026. Effects of a 24-week resistance exercise program on Alzheimer’s disease brain signatures in cognitively unimpaired older adults: a secondary analysis of the AGUEDA randomized controlled trial. Age and Ageing, 2026. DOI: 10.1093/ageing/afag086. PMID: 41967036.
• Zhang 2026b. Effect of multicomponent exercise intervention on older adults with mild cognitive impairment based on HAPA-TPB theory (MIND-STEP): trial design and baseline data for a randomized controlled trial. Trials, 2026. DOI: 10.1186/s13063-026-09640-4. PMID: 41872868.
• Saxton 2026. The impact of exercise interventions before, during, and following neoadjuvant therapies for locally advanced rectal cancer: a critical review. Acta Oncologica, 2026. DOI: 10.2340/1651-226X.2026.44930. PMID: 42159482.
• Papaioannou 2026. Study protocol for a multiarm, randomized controlled trial to determine the effectiveness of community-based frailty rehabilitation to improve physical function in older adults: The OPTIMAL Fitness Trial. PLOS One, 2026. DOI: 10.1371/journal.pone.0343338. PMID: 41818185.
• Hong 2026. Effect of multicomponent exercise intervention on multidimensional frailty in older adults with mild cognitive impairment: a secondary analysis of the MIND-STEP randomised clinical trial. Age Ageing, 2026. DOI: 10.1093/ageing/afag111. PMID: 42059637.
• Cruz-Lopez 2026. Effectiveness of physical exercise on foot pain and function in adults with rheumatoid arthritis: systematic review and meta-analysis. Clinical Rheumatology, 2026. DOI: 10.1007/s10067-026-08044-8. PMID: 41863720.
• Wimo 2026. Impact of an exercise and nutrition program on caregiver time with residents in institutional care—A secondary analysis. Alzheimer's & Dementia, 2026. DOI: 10.1002/alz.71198. PMID: 41690799.
• Huang 2026. Modality-specific effects of structured exercise on immunometabolic biomarkers in postmenopausal obesity: a Bayesian network meta-analysis. Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1763558. PMID: 42148095.
• Huang 2026b. Effects of a smartphone-monitored physical exercise management program on the recovery of patients after endovascular repair of abdominal aortic aneurysm: a randomized controlled trial. Trials, 2026. DOI: 10.1186/s13063-025-08948-x. PMID: 41709331.
• Gong 2026. Effects of exercise on body composition, physical function, and metabolic health in older adults with sarcopenic obesity: A systematic review and meta-analysis. Maturitas, 2026. DOI: 10.1016/j.maturitas.2026.108934. PMID: 41980429.
• Zou 2026. Preferences of frail elderly patients with cardiovascular disease for web-based exercise telerehabilitation interventions in China: protocol for a discrete choice experiment study. BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-111370. PMID: 42161546.
• Azanon-Nogueira 2026. Fun Exercise for Older Adults (FEXO): study protocol for a randomised controlled trial on intrinsic capacity, adherence and motivation. BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-115440. PMID: 42203285.
• Paz-Monton 2026. Physical exercise programmes to improve insomnia or poor sleep quality in non-hospitalised elderly people: a systematic review and meta-analysis. PeerJ, 2026. DOI: 10.7717/peerj.20764. PMID: 41727231.
• Cao 2026. Comparative efficacy of combined exercise and nutritional interventions for sarcopenia: A systematic review and network meta-analysis incorporating remote delivery models. Arch Gerontol Geriatr, 2026. DOI: 10.1016/j.archger.2026.106239. PMID: 41996930.
• Nystoriak 2018. Cardiovascular Effects and Benefits of Exercise. Frontiers in Cardiovascular Medicine, 2018. DOI: 10.3389/fcvm.2018.00135. PMID: 30324108.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Bohannon 1997. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19. DOI: 10.1093/ageing/26.1.15.
• Tinetti 1988. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707. DOI: 10.1056/NEJM198812293192604. PMID: 3205267.
• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.